1Visse R , Nagase H. Matrix metalloproteinase and tissue in hibitors of metalloproteinase: structure , function , and biochemistry[J]. Circ Res, 2003, 92(8) : 827 - 839.
2Montfort I , Perez - Tanayo R. The distribution of collagenase in normal rattissues[J]. J Histochem Cytochem, 1975, 23 ( 12 ) : 910 - 920.
3Tziakas DN, Chalikias GK, Hatzinikolaou El, et al. N - terminal pro - B - type natriuretic peptide and matrix metaUoproteinases in early and late left ventricular remodeling after acute myocardial infarction[J] .Am J Cardiol, 2005, 96(1):31 - 34.
4Kaden JJ, Dempfle CE, Sueselbeck T, et al. Time - dependent in the plasma coneentratDisruption of the myocardial extraeellulaion of matrix metalloproteinase - 9 after acute myocardial infarction [J]. Cardiology, 2003, 99(3) : 140 - 144.
5Etoh T, Joffs C, Deschamps AM, et al. Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs [J] .Am J Physiol Heart Circ Physiol, 2001, 281(3) : 987 - 994.
7Brown DL, Hibbs MS, Kearney M, et al. Identification of 92 KD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina[J]. Circulation, 1995, 91(8) : 2125 - 2131.
8Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metaUoproteinases prevents cardiac rupture but impairs therapeutic magiogenesis and causes cardiac failure [J]. Nat Med, 1999, 5(10) : 1135 - 1142.
9Ducharme A , Frantz S, Aikawa M, et al. Targeted delection of matrix metalloporteinnase - 9 attcunat - Es left ventricular enlargement and collagen accumelation after experimental myocardial infaretionor[J]. J Clin Invest, 2000 , 106 ( 1 ) : 55 - 62.
10Hoit BD, Takeishi Y, CoxMJ , et al. Remodeling of the left atrium in pacing- induced atrial cardiomyopathy[ J ]. Mol Cell Biochem, 2002, 238 (1 - 2) : 145 - 150.
4Spinale FG, Coker ML, Bond BR, et al. Myocardial matrix degradation and metalloproteinase activation in the failing heart : a potential therapeutic target. Cardilvasc Res, 2000, 46:225-238.
6Peterson JT, Li H, Dillon L, et al. Evolution of matrix metalloproteinase and tissue inhibitor expression during heart failure progression int infracted rat. Cardiovasc Res, 2000, 46:307-315.
7Nagahiro N, Kazuhiro Y, Yasushi S, et al. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovasc Res, 2003, 57:766-774.
8Ducharme A , Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest, 2000, 106:55-62.
9Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metallproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure . Nat Med, 1999, 5:1135-1142.
10Borg TK, Burgess ML. Holding it all together: organization and function(s) of the extracellular matrix of the heart. Heart Failure,1993,8 : 230-238.
5Maron D J, Fazio S, Linton MF. Current perspectives on statins [J]. Circulation, 2000, 101 (2): 207-213.
6Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C - reac- tive protein [J]. N Engl J Med, 2008, 359 (21): 2195- 2207.
